Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations

News - Aeterna Zentaris announced that it has selected Charleston, South Carolina as its new location for the Company's North American business and global commercial operations. Over the next five years, Aeterna Zentaris is expected to implement a staff to support the areas of commercial operations, business development, regulatory and quality assurance, manufacturing management, clinical and product development, as well as various administrative functions.

CARTaGENE project seeks 4,000 more participants

News - Launched in 2007, CARTaGENE is an ongoing science project to create a province-wide genetic map with a bank of biological samples collected from Quebecers between age 40 and 69 in six regions: Gatineau, Montreal, Quebec City, Trois-Rivières, Saguenay and Sherbrooke.

New Collaborative Will Improve Respiratory Care - CFHI and Boehringer Ingelheim Partner to Spread INSPIRED Approach to COPD
Aeterna Zentaris: Poster Presentation at AACR Meeting Provides Rationale for New Therapeutic Opportunities in Oncology with Erk Inhibitors

News - Aeterna Zentaris announces that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound. The poster, titled, "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T. Schuster and M. Teifel, was presented yesterday by Irene Seipelt, Ph. D., Director, Preclinical Development at Aeterna Zentaris, during a poster session at the American Association for Cancer Research Annual Meeting in San Diego, California.

Merck Canada announces $2-million grant to support personalized treatment in cancer

News - At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company's continued commitment to the Quebec life sciences research innovation sector by announcing a $2-million grant to the Quebec - Consortium de recherche en oncologie clinique (Q-CROC).

An oral tritherapy that restores walking in paraplegics

News - Crowdfunding campaign for a Quebec-based company developing a tritherapy that can restore 'on-demand' walking for 45 min in experimental models of complete paralysis, wich is being tested in patients.

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego

News - Aeterna Zentaris today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for “At-the-Market” Common Share Issuance Programs

News - Aeterna Zentaris today announced that its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission has been declared effective by the SEC. Under the shelf registration statement, the Company may offer and sell from time to time, in one or more public offerings in the United States, up to $50 million of common shares in one or more "at-the-market" distribution programs, during a 36-month period. The specifics of any particular ATM share issuance program, along with the terms and the use of proceeds of any such common shares offered by the Company will be determined at the time of any such offering and will be described in detail in a prospectus supplement or supplements filed with the SEC at the time of any such offerings.

Scientists identify protein linked to most common movement disorder

News - A team of researchers from Université Laval and CHU de Québec identified unusually high levels of a certain protein in the brains of people suffering from essential tremor (ET), a movement disorder that affects 4% of the adult population. The discovery, the details of which were published in the most recent edition of the journal Movement Disorders, could lead to an effective treatment for this neurological condition, which is 10 times more prevalent than Parkinson’s disease.

Nordic Life Science Pipeline Announces Appointment of a new CFO and Acting CMO

News - Nordic Life Science Pipeline is proud to announce the appointment of Mrs France Tardif as the new Chief Financial Officer of the company as well as of Dr. Kevin O’Connor, our new acting Chief Medical Officer.


Jean-MichelGarroLife Sciences

More details


Subscribe to our newsletter for interesting news and information.

Print this page